Premium
Lamotrigine in bipolar disorder: efficacy during pregnancy
Author(s) -
Newport D Jeffrey,
Stowe Zachary N,
Viguera Adele C,
Calamaras Martha R,
Juric Sandra,
Knight Bettina,
Pennell Page B,
Baldessarini Ross J
Publication year - 2008
Publication title -
bipolar disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.285
H-Index - 129
eISSN - 1399-5618
pISSN - 1398-5647
DOI - 10.1111/j.1399-5618.2007.00565.x
Subject(s) - lamotrigine , bipolar disorder , pregnancy , medicine , psychiatry , clinical neurology , psychology , epilepsy , neuroscience , mood , biology , genetics
Objective: Clinical management of bipolar disorder (BPD) patients during pregnancy is a major challenge. The high risk of bipolar depression during pregnancy encourages consideration of lamotrigine (LTG). We therefore compared recurrence risks among pregnant women with BPD treated with LTG to those discontinuing mood stabilizer therapies. Methods: We compared risks and weeks to new DSM‐IV illness‐episodes among 26 initially clinically stable pregnant women diagnosed with DSM‐IV BPD who continued LTG treatment to those discontinuing all mood stabilizer treatment during pregnancy. Results: The risk of new illness‐episodes with LTG was 30% versus 100% after discontinuing mood stabilizers, and survival‐computed time‐to‐25%‐recurrence was 28.0 versus 2.0 weeks (χ 2 = 17.3, p < 0.0001; hazard ratio = 12.1; 95% confidence interval = 1.6–91.7). Conclusions: Discontinuing mood stabilizer treatment presents high risks of illness‐recurrence among pregnant women diagnosed with BPD. LTG may afford protective effects in pregnancy, and its reported fetal safety compares favorably to other agents used to manage BPD.